Chromosome 17 Abnormalities and Inactivation of the P53 Gene in Chronic Myeloid Leukemia and Their Prognostic Significance
- 1 January 1995
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 19 (3-4) , 213-221
- https://doi.org/10.3109/10428199509107891
Abstract
We have reviewed all the relevant studies on the loss of the short arm of chromosome 17 (17p) and inactivation of the p53 gene in chronic myelogenous leukemia (CML) in an attempt to clarify their roles in the progression of CML. Loss of a I7p (hemizygous I7p) and p53 inactivation emerged as the disease progressed and were closely associated with each other. About half of the cases with loss of a 17p, however, did not show pS3 inactivation. In these cases loss of a 17p preceded p53 inactivation, which suggested that either reduction of the p53 gene dosage or inactivation of another tumor-sup pressor gene on I7p might contribute to the diseasc progression. Both loss of a I7p and pS3 inactiation may serve as poor prognostic factors but the prognostic significance of the former only emerged when metaphase cells with loss of a 17p were dominant amongst the total cell population analyzed.Keywords
This publication has 42 references indexed in Scilit:
- Multiple aberrant splicing of the p53 transcript without genomic mutations around exon‐intron junctions in a case of chronic myelogenous leukaemia in blast crisis: a possible novel mechanism of p53 inactivationBritish Journal of Haematology, 1994
- Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemiaBritish Journal of Haematology, 1994
- Myelomonocytic crisis with t(5;17) and a p53 mutation in a patient with chronic myelogenous leukemiaAmerican Journal of Hematology, 1994
- Clues to the Pathogenesis of Familial Colorectal CancerScience, 1993
- p 53 gene rearrangements in chronic myelocytic leukemiaAnnals of Hematology, 1993
- p53, guardian of the genomeNature, 1992
- p53 Mutations in Human CancersScience, 1991
- The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.Journal of Clinical Investigation, 1991
- Geographic heterogeneity of neoplasia‐associated chromosome aberrationsGenes, Chromosomes and Cancer, 1991
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990